The California Stem Cell Research Institute Bond Initiative (#19-0022) may appear on the ballot in California as an initiated state statute on November 3, 2020.
The ballot initiative would issue $5.5 billion in general obligation bonds for the California Institute for Regenerative Medicine (CIRM), which was created to fund stem cell research. The ballot initiative would require CIRM to spend no more than 7.5 percent of the bond funds on operation costs. The remaining bond funds would be spent on grants to entities that conduct research, trials, and programs related to stem cells, as well as start-up costs for facilities.[1]
The official ballot title is as follows:[2]
Authorizes Bonds to Continue Funding Stem Cell and Other Medical Research. Initiative Statute.[3]
The summary provided for inclusion on signature petition sheets is as follows:[2]
Authorizes $5.5 billion in state general obligation bonds to fund grants from the California Institute of Regenerative Medicine to educational, non-profit, and private entities for: (1) stem cell and other medical research, therapy development, and therapy delivery; (2) medical training; and (3) construction of research facilities. Dedicates $1.5 billion to fund research and therapy for Alzheimers, Parkinsons, stroke, epilepsy, and other brain and central nervous system diseases and conditions. Limits bond issuance to $540 million annually. Appropriates money from General Fund to repay bond debt, but postpones repayment for first five years.[3]
The fiscal impact statement is as follows:[2]
State costs of $7.8 billion to pay off principal ($5.5 billion) and interest ($2.3 billion) on the bonds. Associated average annual debt payments of about $310 million for 25 years. The costs could be higher or lower than these estimates depending on factors such as the interest rate and the period of time over which the bonds are repaid. The state General Fund would pay most of the costs, with a relatively small amount of interest repaid by bond proceeds.[3]
The full text of the ballot measure is available here.
Californians for Stem Cell Research, Treatments & Cures is leading the campaign in support of the ballot initiative.[4]
Ballotpedia has not identified individuals and entities opposing the ballot initiative. If you are aware of published opposition to the ballot initiative, you may send a reference link to editor@ballotpedia.org.
The Californians for Stem Cell Research, Treatments & Cures PAC was registered to support the ballot initiative. The committee had raised $6.06 million. Robert N. Klein II and Klein Financial Corporation provided $4.63 million to the PAC. The committee had expended $8.72 million (expenditures exceeded contributions due to accrued expenses).[6]
There were no PACs registered to oppose the ballot initiative.[6]
The following table includes contribution and expenditure totals for the committee in support of the ballot initiative.[6]
The following was the top donors to the support committee.[6]
In 2004, voters approved Proposition 71, which was a ballot initiative designed to establish a state constitutional right to conduct stem cell research, create the California Institute for Regenerative Medicine (CIRM), and issue $3.00 billion in general obligation bonds to fund CIRM.[7]
As of October 2019, CIRM had spent $2.91 billion of the $3.00 billion bond issue.[8]
In California, the number of signatures required for an initiated state statute is equal to 5 percent of the votes cast in the preceding gubernatorial election. Petitions are allowed to circulate for 180 days from the date the attorney general prepares the petition language. Signatures need to be certified at least 131 days before the general election. As the verification process can take multiple months, the secretary of state provides suggested deadlines for ballot initiatives.
The requirements to get initiated state statutes certified for the 2020 ballot:
Signatures are first filed with local election officials, who determine the total number of signatures submitted. If the total number is equal to at least 100 percent of the required signatures, then local election officials perform a random check of signatures submitted in their counties. If the random sample estimates that more than 110 percent of the required number of signatures are valid, the initiative is eligible for the ballot. If the random sample estimates that between 95 and 110 percent of the required number of signatures are valid, a full check of signatures is done to determine the total number of valid signatures. If less than 95 percent are estimated to be valid, the initiative does not make the ballot.
On October 10, 2019, Robert N. Klein filed the ballot initiative.[1] Attorney General Xavier Becerra (D) released ballot language for the initiative on December 17, 2019, which allowed proponents to begin collecting signatures. The deadline to file signatures is June 15, 2020.
Political responses overviewState reopening plansDocumenting America's Path to RecoveryDaily updatesElection changesChanges to vote-by-mail and absentee voting proceduresFederal responsesState responsesState executive ordersStay-at-home ordersMultistate agreementsNon-governmental reopening plansEvictions and foreclosures policiesTravel restrictionsEnacted state legislationState legislative session changesSchool closuresState court closuresInmate releasesLocal government responsesDiagnosed or quarantined politiciansBallot measure changesArguments about government responsesThe 1918 influenza pandemicPandemic Response Accountability CommitteeUnemployment filingsLawsuitsSubmit
On February 13, 2020, proponents announced that the number of collected signatures surpassed the 25-percent threshold (155,803 signatures) to require legislative hearings on the ballot initiative.[9] In 2014, Senate Bill 1253 was enacted into law, which required the legislature to assign ballot initiatives that meet the 25-percent threshold to committees to hold joint public hearings on the initiatives not later than 131 days before the election.
On March 21, 2020, Sarah Melbostad, a spokeswoman for Californians for Stem Cell Research, Treatments, and Cures, reported that the campaign's signature drive was suspended due to the coronavirus pandemic. Melbostad said, "In keeping with the governors statewide order for non-essential businesses to close and residents to remain at home, weve suspended all signature gathering for the time being. ... Were confident that we still have time to qualify and plan to proceed accordingly."[10]
On May 5, 2020, the campaign reported submitting about 925,000 signatures for the ballot initiative.[11] At least 623,212 of the signatures need to be valid. The recommended deadline to file signatures for the election on November 3, 2020, was April 21, 2020. Counties need to validate the signatures before June 25, 2020, for the ballot initiative to appear on the ballot in 2020. Otherwise, the ballot initiative would appear on the ballot on November 8, 2022.
Here is the original post:
California Stem Cell Research Institute Bond Initiative (2020)
- Stem Cell Therapy for Treatment of Ocular Disorders - Hindawi - December 27th, 2022
- Researchers find out why some stress is good for you - November 6th, 2022
- Shinya Yamanaka - Wikipedia - October 29th, 2022
- Implanting a Patient's Own Reprogrammed Stem Cells Shows Early Positive ... - October 29th, 2022
- World's first stem cell treatment for spina bifida delivered during fetal surgery - UC Davis Health - October 13th, 2022
- JDRF Announces the Appointment of Qizhi Tang, Ph.D., as Co-Director of The JDRF Center of Excellence in Northern California - PR Newswire - October 13th, 2022
- California court creates regulatory uncertainty over the FDA regulation of stem cell therapies - BioEdge - October 4th, 2022
- Scientists have created a mechanical womb that can grow life in the lab - Inverse - October 4th, 2022
- ISCT: California stem cell ruling is flawed and has inserted regulatory uncertainty into the CGT market - BioPharma-Reporter.com - September 16th, 2022
- Scientists Use Stem Cells to Create Synthetic Mouse Embryos - September 16th, 2022
- UK Equine Research Hall of Fame Inductees Announced - Equi Management - September 16th, 2022
- Cultured meat startup Prolific Machines unveils its Henry Ford approach to cell growth - TechCrunch - September 16th, 2022
- New Stem Cell Therapy Protects Brain Against the Neurological Disorder - Nature World News - September 8th, 2022
- Scientists Are Working on New and Improved Hair Loss Treatments - Gizmodo - September 8th, 2022
- What happens to the brain on prescription steroids? - Medical News Today - September 8th, 2022
- How this scientist uses Legos to explain the power of stem cells - August 30th, 2022
- CIRM Bridges intern researches stem cells to grow kidneys - August 30th, 2022
- Alzheimer's: Could controlling the brain's own clean-up crew help? - Medical News Today - August 22nd, 2022
- Trial to Compare Safety and Efficacy of Novel Cell Therapy to Standard of Care in Patients With Rare Blood Cancers - Curetoday.com - August 5th, 2022
- Medpoint Global was awarded the Best Revolutionary Hair Transplant Center of the Year and continues to follow developments in its field and offer more... - August 5th, 2022
- Cell Culture Media Market Worth $14.64 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - August 5th, 2022
- Haifan Lin takes on new role as President of the ISSCR - EurekAlert - July 3rd, 2022
- UCI-led team discovers signaling molecule that potently stimulates hair growth - UCI News - July 3rd, 2022
- Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board - Business Wire - July 3rd, 2022
- Organoids reveal similarities between myotonic dystrophy type 1 and Rett syndrome - EurekAlert - July 3rd, 2022
- Our View: Roe reversal hard hit to science - The Durango Herald - July 3rd, 2022
- Connection Map Reveals Changes in the Injured Brain - Technology Networks - June 22nd, 2022
- Scientists Used CRISPR to Trace Every Human Gene to Its Function - Singularity Hub - June 22nd, 2022
- Maike Sander named to lead the Max Delbrck Center - EurekAlert - June 22nd, 2022
- CRISPR-Cas12a Editing Rates Improve with Better Directions to the Nucleus - Genetic Engineering & Biotechnology News - June 22nd, 2022
- UB-led study presents critical step forward in understanding Parkinson's disease and how to treat it - University at Buffalo - June 13th, 2022
- Stem Cells: A Case for the Use of Human Embryos in Scientific Research - June 4th, 2022
- Top Beverly Hills Plastic Surgeon, Dr. John Anastasatos, Explores Cell-Assisted Lipotransfer (CAL) with Breast Augmentation in New Publication -... - June 4th, 2022
- Regenerative Medicine Market To Grow At A CAGR Of 11.27% By 2027, Due To Advancements In Cell Biology, Genomics Research, And Gene-Editing Technology... - June 4th, 2022
- Google Reverses Ban on Ads for All Stem Cell Therapies, Will Allow FDA-Approved Ones - Gizmodo Australia - May 15th, 2022
- Head-To-Head Survey: Jasper Therapeutics (NASDAQ:JSPR) & CytRx (OTCMKTS:CYTR) - Defense World - May 15th, 2022
- Primary Cell Culture Market Mechanical Separation Segment Is Expected To Witness A Lucrative CAGR Of 11.7% Till 2028, Owing To Advancements In... - May 15th, 2022
- Ray Therapeutics Receives $4M in Funding From the California Institute for Regenerative Medicine (CIRM) - BioSpace - May 2nd, 2022
- Predicting the Future of Food - Bon Appetit - May 2nd, 2022
- FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS USA - English -... - April 19th, 2022
- Chronic Diseases Is Expected To Have Positive Impact On Stem Cell Characterization Kits Market Demand Bloomingprairieonline - Bloomingprairieonline - April 19th, 2022
- Cleveland Cord Blood Center and Deverra Therapeutics Announce Agreement - Yahoo Finance - April 6th, 2022
- A model that mimics malformation associated with severe epilepsy paves way to novel therapies - EurekAlert - March 25th, 2022
- Stem cell agency: Following the money - and its performance - Capitol Weekly - December 24th, 2021
- Epithelial Cell Culture Media Market to hit US$ 303040.33 thousand by 2028, at 11.4% CAGR: The Insight Partners - Digital Journal - December 24th, 2021
- What is Biohacking? Understanding the Silicon Valley Wellness Trend Youll Hear About in 2022 - SheKnows - December 24th, 2021
- Second Woman Spontaneously Clears HIV: 'We Think More Are Out - Medscape - November 22nd, 2021
- Business Partnership for Development and Commercialization of Medical Device Implant Utilizing MSC2 for the Regeneration of Esophageal Tissue in... - November 22nd, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert - October 16th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 16th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WSAW - October 5th, 2021
- BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - WWNY - October 5th, 2021
- UC Davis and the School of Medicine set new records in research funding - UC Davis Health - August 31st, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 21st, 2021
- Stem cell model reveals how COVID-19 can infect the brain - Study Finds - July 21st, 2021
- Introducing the 3D bioprinted neural tissues with the potential to 'cure' human paralysis - 3D Printing Industry - July 21st, 2021
- Insception Lifebank and Cells for Life Join the Generate Life Sciences Family to Create a Global Platform - Canada NewsWire - June 6th, 2021
- Innovative Regenerative Medicine Therapies Safety Comes First - FDA.gov - June 6th, 2021
- ViaCyte to Present Late-Breaking Data at the American Diabetes Association's 81st Scientific Sessions - PRNewswire - June 6th, 2021
- Viral vector unlikely to be cause of leukemia in gene therapy patient - Science Magazine - March 11th, 2021
- Astrocytes Derived from Patients with Bipolar Disorder Malfunction - UC San Diego Health - March 11th, 2021
- Peer Recognition | The UCSB Current - The UCSB Current - March 11th, 2021
- Stem cells on the ballot - Science Magazine - January 20th, 2021
- Controlling the immune system with 'invisible stem' cells - BioNews - January 20th, 2021
- How a UCSF team is giving Cronutt the sea lion a second chance with neuroscience - University of California - October 20th, 2020
- What Proposition 14 Tells Us About California - The New York Times - October 20th, 2020
- California Proposition 14: Funding medical research that uses stem cells - KTLA - October 20th, 2020
- Technology to natures rescue - The Hindu - October 20th, 2020
- What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) - KQED - October 5th, 2020
- UC Davis Engineers Lead $36M Effort to Improve Recovery From Spinal Cord Injuries - UC Davis - October 5th, 2020
- Dust off the crystal ball: It's time for STAT's 2020 Nobel Prize predictions - STAT - October 5th, 2020
- Stem Cells Offer Hope of Treatment for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS) - HospiMedica - September 15th, 2020
- David Shavelle, MD, Named Medical Director of Adult Cardiology for the MemorialCare Heart & Vascular Institute at Long Beach Medical Center -... - September 15th, 2020
- Seeing the eye like never before | Newsroom - UW Medicine Newsroom - September 15th, 2020
- Why The FDA's Recent Approval Of New Vaccine Is A Gigantic Win In The War On Cancer - Innovation & Tech Today - September 7th, 2020
- Gore partners with San Diego company on cell delivery system with potential to treat Type 1 diabetes - delawarebusinessnow.com - August 12th, 2020
- Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 - PRNewswire - August 12th, 2020
- Meet The 12 Next-Gen Food Techs Transforming The Future Of Protein - Green Queen Media - August 12th, 2020
- BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the US - BioSpace - August 12th, 2020
- BCLI: Phase 3 ALS Data Expected by the End of November 2020 - Yahoo Finance - August 12th, 2020